Author's response to reviews

Title: Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis

Authors:

Jaana Kaunisto (jakrja@utu.fi)
Katariina Kelloniemi (katariina.kelloniemi@hus.fi)
Eva Sutinen (eva.sutinen@helsinki.fi)
Ulla Hodgson (ulla.hodgson@hus.fi)
Anneli Piilonen (anneli.piilonen@hus.fi)
Riitta Kaarteenaho (Riitta.Kaarteenaho@oulu.fi)
Riitta Mäkitaro (riitta.makitaro@ppshp.fi)
Minna Purokivi (minna.purokivi@kuh.fi)
Eija-Riitta Salomaa (eija-riitta.salomaa@fimnet.fi)
Seppo Saarelainen (seppo.saarelainen@pshp.fi)
Hannu Kankaanranta (hannu.kankaanranta@epshp.fi)
Merja Kanervisto (merja.kanervisto@filha.fi)
Arja Mursu (arja.mursu@fimnet.fi)
Marjukka Mylläriemi (marjukka.mylarriemi@helsinki.fi)
Elisa Lappi-Blanco (Elisa.Lappi-Blanco@ppshp.fi)

Version: 4  Date: 3 July 2015

Author's response to reviews: see over
Title: Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis


Dear Editor,

We are happy to hear that both the editorial board and reviewers were pleased with the changes made. One of the reviewers suggested two additional revisions which are now fulfilled.

Please find attached the revised version of the manuscript with changes highlighted in red and a point-by-point response to the reviewer’s comments (below).

We look forward to seeing our manuscript in your journal.

Yours sincerely,

Jaana Kaunisto
Eija-Riitta Salomaa
Marjukka Myllärniemi
Here below, please find our point-by-point responses to reviewer’s revisions.

Reviewer 2:

**Results; use acronym IPF instead of the complete name (idiopathic pulmonary fibrosis).**

This has now been changed as suggested (p.7, line 172)

**Discussion; about drug future reimbursement, it would interesting to point that almost 10 % of cases died after 3-4 years from diagnosis although they were diagnosed in a functional mild-moderate stage.**

This is a good point, thank you. See Discussion p. 10, lines 233-235.